Citeline Podcasts

The latest episode of the In Vivo podcast features an interview Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Astellas is doubling down on gene therapy while others retreat. Richard Wilson, SVP Primary Focus Lead, Genetic Regulation at Astellas, joins In Vivo to discuss why the company believes AAV technology will transform medicine despite current industry headwinds.

🎯 Key Topics:

- Why Astellas opened a massive new gene therapy manufacturing facility

- Building an end-to-end AAV platform from research to commercial

- Strategic partnerships driving CNS and rare disease programs

- Maintaining team morale in a challenging investment climate

- Regulatory outlook and the path to commercial success

Richard also plays a role in Astellas' West Coast Innovation Center and serves on the Alliance for Regenerative Medicine board. He shares insights on manufacturing at scale, patient-centric culture, and the long-term potential of gene therapy.

Perfect for biotech investors, pharma executives, and anyone tracking the evolution of genetic medicines.

🔗 More insights: insights.citeline.com/in-vivo

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 11, 2025. In this episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.

https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-TJX4YBGD5JDSHGRUTLYHWO2JMU/

This episode was produced with the help of AI text-to-voice and voice emulation tools.

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Originally developed to treat diabetes, GLP-1 agonists have been found to suppress appetite and reduce calorie intake, fueling their growing popularity as obesity drugs. According to JP Morgan, the total number of GLP-1 users in the US may reach 30m by 2030, or around 9% of the population. But what is the opportunity for the consumer health industry? According to Kerry Group’s scientific director Mathieu Millette, there are two main areas that companies could target. Firstly, there are the pre-and post-GLP phases, when consumers may want natural GLP-1 alternatives to help them lose weight or maintain the weight loss achieved on the drug. And secondly, during use, consumer health products can help address some of the unwanted side-effects of GLP-1s, for example gastrointestinal issues. Of course, as Millette tells HBW insight in this episode of the Over the Counter podcast, marketers also need to be mindful of the regulatory environment around health claims, especially in the EU.

Timestamps

2:20 – Introductions

3:30 – What are GLP-1 agonists?

8:50 – What’s the opportunity for consumer health companies?

16:00 – Is this a European trend as well?

17:40 – Health claims: the regulatory environment

25:00 – Natural GLP-1 alternatives

Guest Bio

Mathieu Millette is scientific director for Bio-K Plus International and RDA director for digestive health within Kerry Group’s proactive health division. Millette leads a team of talented scientists dedicated to elucidating the mechanisms of action of probiotics and to understanding the interactions between beneficial microorganisms, the gut microbiome, and the gastrointestinal tract. Millette is also associate professor at INRS-IAF, a member of the Association of Microbiologists of Quebec and is highly involved with the International Probiotic Association.

올해 제약바이오 M&A 가 다소 주춤할 것으로 전망되고 있지만, 재정난을 겪고 있는 의약품 개발업체들이 자금조달의 대안을 찾으면서 잠재적 매물이 넘쳐나고 있다는 Scrip의 BIO USA 기사를 요약한 내용입니다.

https://insights.citeline.com/scrip/conferences/bio/bio-deal-trends-financial-market-stress-creates-transactional-opportunities-IL5W6U4BSZD6RPQ53EHG7HNTJ4/

Playlist: soundcloud.com/citelinesounds/sets/korean-language-biopharma-mini

The latest episode of the In Vivo podcast features an interview with Phil L'Huillier, who discusses the inclusion of Scancell's melanoma cancer vaccine on the NHS Cancer Vaccine Launch Pad, and how 2025 could be a pivotal year for the cancer vaccine field as a whole.

Ying Tam, Chief Scientific Officer at Acuitas Therapeutics, discusses the company's role in delivering the first personalized CRISPR gene editing treatment to an infant with CPS-1, achieving treatment in just six months from diagnosis. Tam shares insights on evolving lipid nanoparticle technology beyond COVID vaccines, including LNPs that allow for next-generation immune-targeting delivery that is 10x more potent, and progress in delivering genetic medicines to stem cells and solid tumors. He also addresses the challenges of repeat dosing, a new biodegradable LNP formulation, and expanding genetic medicine beyond the liver to treat blood disorders and cancer.

The latest episode of the In Vivo podcast features an conversation with Agnès Arbat, CEO and co-founder of Barcelona-based biotech company OxoLife, which is pioneering a novel approach to addressing female infertility.

According to a recently published study by Bayer Consumer Health, being poor makes it more likely that you will suffer from self-treatable health conditions. But it also means you will find it harder to take advantage of self-care solutions. In this episode of the Over the Counter podcast, HBW Insight speaks to Bayer Consumer Health’s global medical access lead Emese Csoke about the issues that the study raises for the self-care industry, not least how widening access to self-care solutions can be balanced with equity with regards to affordability. For Csoke, ways forward include partnerships between public and private sector stakeholders and investments in digital self-care.

Timestamps

2:00 – Introductions

2:50 – Bayer Consumer Health’s RISE initiative

4:00 – Self-care is hardest for those who need it most

5:45 – Implications for the consumer health industry

8:20 – Self-care’s “double burden”

10:15 – Profit vs people?

16:30 – Public-private partnerships

19:00 – Digital self-care

22:40 – Impact of RISE so far

Guest Bio

Emese Csoke is currently serving as global strategy director for regulatory, medical, safety, quality, and compliance at Bayer Consumer Health. In this role, she plays a pivotal part in advancing health equity by designing and implementing strategic initiatives that expand access to self-care. Emese led the creation of the strategic pillar RISE – the Research Initiative for Self-care Equity – and authored a peer-reviewed publication on the impact of socioeconomic determinants on health outcomes for self-care conditions. As a lead on Bayer’s “dynamic shared ownership” model, Csoke is also driving force behind organizational transformation and innovation. Csoke holds a PharmD and a degree in Clinical Development Science from Semmelweis University and is certified as a medical science translator.

Audio roundup of selected biopharma industry content from Scrip over the business week ended July 4, 2025. In this episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.

https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-Y77FXMFAIFEVFK75G5QUSNSBOY/

This episode was produced with the help of AI text-to-voice and voice emulation tools.

Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things